Cytokinetics, Incorporated (Nasdaq: CYTK) gab heute den erfolgreichen Abschluss seiner Phase-IIa - Studie:
"Evidence of Effect" (EOE) klinische Studie mit CK-2017357 bei Patienten mit Amyotrophe Lateralsklerose (ALS) bekant, auch als Lou-Gehrig-Krankheit genannt, während einer mündlichen Präsentation, die in der Clinical Trials Session auf dem 21. International Symposium on ALS / MND in Orlando, Florida.
South San Francisco, CA - December 13, 2010
Cytokinetics, Incorporated (Nasdaq:CYTK) announced the successful completion of its Phase IIa “Evidence of Effect” (EoE) clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, during an oral presentation included in the Clinical Trials Session at the 21st International Symposium on ALS/MND in Orlando, Florida.
A presentation titled, “A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, Single-dose, Crossover Study of the Selective Fast Skeletal Muscle Troponin Activator, CK-2017357, in Patients with ALS” was made by Jeremy M. Shefner, MD, PhD, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York. CK-2017357 is the lead drug candidate from the company's skeletal muscle contractility program.
“We are pleased that this clinical trial has successfully generated results in patients with ALS that are both encouraging and consistent with data generated in our preclinical studies and our Phase I clinical trials with CK-2017357. Importantly, this clinical trial has now generated clinically relevant hypotheses that warrant further exploration in proof-of-concept clinical trials in patients with ALS,” stated Andrew A. Wolff, MD, FACC, Cytokinetics’ Senior Vice President of Clinical Research and Development and Chief Medical Officer. “We are now planning to proceed into a multiple-dose clinical trial to understand how longer-term dosing of CK-2017357 may impact the functional status of these patients.”
“This study suggests that CK-2017357 may play a significant role in the treatment of patients with ALS,” stated Dr. Shefner. “We assessed multiple variables associated with muscle function in these patients. Based on these encouraging results, I believe that CK-2017357 may offer a new way of thinking about symptom relief and quality of life for these patients. These results support further study of CK-2017357 to evaluate the potential for sustained functional benefit in patients with ALS.”
|aus der Diskussion:||ALS - Biotech machts möglich?|
|Autor (Datum des Eintrages):||Karl79 (13.12.10 17:23:26)|
|Beitrag:||1 von 9 (ID:40701725)|
|Alle Angaben ohne Gewähr © wallstreet:online|